1 Real-world study of Cerviron[®] vaginal ovules in the treatment of cervical lesions of various

2 etiologies

3 IZABELLA PETRE^{1,2}, DANIELA TEODORA SIRBU³, RAMONA PETRITA⁴, ANDREEA 4 DENISA TOMA⁵, EMA PETA⁶ AND FLORENTINA DIMCEVICI-POESINA⁶

5

¹Discipline of Obstetrics and Gynecology XII, 'Victor Babes' University of Medicine and Pharmacy, 300041
Timisoara; ²University Clinic of Obstetrics and Gynecology, Emergency Clinic Hospital 'Pius Brinzeu', 300226
Timisoara; ³Dr Sirbu Daniela Private Practice, 300269 Timisoara; ⁴Biometrics Unit, MDX Research, 300633
Timisoara; ⁵Pharmacy Unit of Municipal Hospital 'Dr Karl Diel' Jimbolia, 305400 Jimbolia; ⁶Quality Assurance,
Perfect Care Distribution SRL, Bucharest, Romania

11

12 Correspondence to: Mrs Ramona Petrita, Biometrics Unit, MDX Research Romania, 1-3 Vasile Loichita Street,

13 300633 Timisoara, Romania; E-mail: <u>ramona.petrita@mdxresearch.eu</u>

14 Dr Izabella Petre, Discipline of Obstetrics and Gynecology XII, 'Victor Babes' University of Medicine and

15 Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara; E-mail: dr.petreizabella@yahoo.com

16

17 Abstract. Cervical lesions can be caused by pathogens, hormonal changes or by cervical injury. 18 The recommended treatment in all cases is excision. Local re-epithelialization therapy should be 19 initiated preoperatively and postoperatively. The present study assessed the post-market performance and tolerability of Cerviron[®] ovules in the treatment and management of cervical 20 21 lesions postoperatively. The study population included 345 participants aged 20-70 years with 22 either a cervical lesion under treatment or with recent surgical removal of a cervical lesion. The 23 degree of re-epithelialization of the cervical mucosa was improved in 73.17% of the patients 24 evaluated during routine colposcopy exams and 92.73% of patients recorded no bleeding. When adding Cerviron[®] either as monotherapy or in association with other antimicrobials in 25 26 postoperative care of the cervical ectropion, improved postoperative outcomes such as reduced 27 post-interventional bleeding and a superior quality of healing were observed. The study and its details are registered in www.clinicaltrials.gov under ID NCT05668806. 28

29 Key words: medical device, cervical lesions, cervical mucosa, vaginal pH, vaginal pain, vaginal bleeding

30 Introduction

A cervical erosion (or cervical ectropion) can occur for numerous reasons among women of childbearing age (1). It is considered a benign condition caused by pathogens or induced by increased exposure of the cervical epithelium to estrogen. Moreover, cervical erosions can be of traumatic, mechanical etiology, such as intrauterine devices or foreign bodies introduced into the vagina (2). Its prevalence ranges from 17 to 50% (3,4). The presence of ectropion is detected especially after the menarche, during pregnancy or with use of the combined oral contraceptive pill and is very rare in postmenopausal women (5).

38 Epithelialization of the vaginal mucus and cervix is crucial in the management of cervical 39 erosions. Acute inflammation of the cervix as a result from direct infection or trauma translates 40 into several symptoms, such as white to yellow vaginal discharge (predominant symptom caused 41 by the mucus-secreting glandular epithelium), post-coital or intermenstrual bleeding, dysuria, 42 pelvic pain, vulvovaginal irritation and dyspareunia (6). Symptomatic women should be screened 43 for infective agents (7). Cervical ectropion has been associated with both the combined oral 44 contraceptive pill and intrauterine contraceptive devices as highlighted by the study conducted 45 by Wright et al (4). Concurrently, a number of studies have highlighted that the use of combined 46 oral contraceptives is highly associated with the development of cervical ectopy, edema and 47 erythema of the ectopic zone (7-9).

48 Pathogens such as streptococci, staphylococci, or enterococci can be promoters of acute 49 inflammation of the cervix and cervical ectropion (10). Cervicitis (inflammation of the cervix) is 50 often asymptomatic and can cause complications of the upper genital tract with ectopia and 51 cervical infection by Chlamidia trachomatis, Neisseria gonorrhoeae, herpes simplex virus, and 52 cytomegalovirus (11). Some factors involved in the pathogenesis of cervical ectopy involve the 53 action of estrogen (12). Estrogens influence immune and inflammatory processes, by regulating 54 chemokines and chemokine receptors. In a previous study by Straub, the complex processes of 55 inflammation related to estrogen signaling toward immune cell trafficking were studied (13). The 56 T helper 17 cells producing IL-17 are the main T cells responsible for chronic inflammation. The 57 cervical epithelium is highly responsive to estrogen production. Mechanistically, it is considered 58 that estrogens induce apoptosis in cervical cells and also increase gene expression of human 59 papillomavirus-16 and -18, the two genotypes frequently associated with cervical cancer (14). 60 Exposure to high levels of estrogen is also linked to an increased risk of breast cancer (15). 61 Estrogen influences immune and inflammatory processes by modulating the production of pro-62 inflammatory cytokines, chemokines and other immune mediators. Specifically, estrogen can 63 activate pathways that lead to the production of anti-inflammatory cytokines, such as interleukin-64 4 (IL-4), and chemokines, such as interferon- γ (IFN- γ) (16). Furthermore, estrogen can inhibit the production of pro-inflammatory mediators such as tumor necrosis factor (TNF) and IL-6. 65 66 Estrogen can also regulate the expression of chemokine receptors on immune cells, which in turn 67 helps regulate the migration of immune cells to sites of inflammation (17). For example, estrogen 68 can downregulate the expression of the CCR5 receptor, which is involved in the migration of T 69 cells to sites of inflammation. Estrogen can also upregulate the expression of the CXCR4 70 receptor, which is involved in the migration of macrophages and neutrophils to sites of 71 inflammation (18).

72 The presence of endocervical columnar epithelium on the ectocervix favors an increased 73 exposure to infections due to low cell-mediated immunity. In these areas, the subpopulation of T 74 lymphocytes, namely, T helper cells, CD8 cells, and CD1 lymphocytes are reduced in number 75 (19). Therefore, the columnar epithelium cells are more susceptible to infections such as 76 Chlamydia trachomatis or Neisseria gonorrhoeae (20). Estrogens are capable of markedly 77 altering the responses of host cells to microbes. In adolescence, pregnancy, during hormonal 78 contraception, or during the years of menstruation (mostly in the ovulatory phase), the 79 probability of developing cervical ectopy is very high, and sometimes goes undetected (5). 80 Furthermore, cervical ectopy implies further risks of acquiring sexually-transmitted diseases 81 (gonorrhea, chlamydia and human papilloma virus). In the study conducted by Sanchez et al a 82 causal relationship was found between cervical erosion and bacterial vaginosis that alter the 83 mucosal barrier and decrease defense mechanisms of the cervix and vagina (21).

An ongoing debate remains of whether ectopy requires a specific treatment. The association between squamous metaplasia and induction of squamous cell carcinoma of the cervix is well known. Moreover, the dysplastic cells are more susceptible to carcinogens (22). Notwithstanding this, according to a recent study conducted by Kleppa *et al*, ectopy may be a biological risk factor for chlamydia infection and for human immunodeficiency virus (HIV) in adolescents and in young women (7). 90 Currently, cryotherapy (cryosurgery) of the cervix is the standard treatment for symptomatic, 91 benign cervical ectropion (23). Cryosurgery improves the cervical mucus characteristics and 92 therefore it is recommended in patients with hostile cervical mucus and ectropion (24). Prior to 93 and after surgery, adjuvant treatments should be promoted with the support of local, re-94 epithelizing treatments (25). For example, Belfiore *et al* reported the effectiveness of a topical 95 treatment for cervical ectropion with 5 mg of deoxyribonucleic acid (26).

96 Cerviron has a substance content that provides beneficial properties in non-infectious 100 97 vulvovaginitis and cervical erosion. The ovule melts in the vaginal mucosa forming a cream that 101 98 ensures dispersion of the substances contained and acts as a protective barrier with astringent 102 99 effect, favoring the reepithelization of damaged tissue and the restoration of the initial 103 100 colpoecosystem without affecting the Doderlein bacilli. The main mechanism of action of the 104 101 medical device is the dispersion of the substances in the vagina and the formation of a protective 105 102 barrier that accelerates the natural healing process of the damaged epithelium. Performance and safety data on Cerviron[®] vaginal ovules have been reported from multiple sources. Three clinical 103 104 investigations on Cerviron were reported (NCT04735705, NCT04735718 and NCT05652959 105 available at https://clinicaltrials.gov/ct2/show/NCT04735705; 106 https://clinicaltrials.gov/ct2/show/NCT04735718; and

107 <u>https://clinicaltrials.gov/ct2/show/NCT05652959</u>, respectively) and published articles on 108 Cerviron[®] include the characterization of its utility in the management of cervical uterine 109 fibroids and on vaginal atrophy after surgical treatment and adjuvant radiation therapy for 110 cervical cancer (27,28). However, previous safety data was limited and included only a 111 restricted, homogenous population, including 50 participants in study NCT04735705 and only 27 112 participants in study NCT04735718.

113 Cerviron[®] is a medical device marketed by Perfect Care Distribution in the following 114 countries: Albania, Latvia, Lithuania, Estonia, Kosovo, Montenegro, Romania, Kuwait, and the 115 United Arab Emirates. With a complex composition consisting of three topical pharmaceutical 116 products including hexylresorcinol, collagen and bismuth subgallate, and four phytotherapeutic 117 extracts including *Calendula officinalis*, *Hydrastis canadensis*, *Thymus vulgaris* extract and 118 *Curcuma longa*, it is intended as adjuvant treatment for the management of cervical lesions and 119 vulvovaginitis.

120 Materials and methods

Study objectives. The present study was designed as part of the medical device post-marketing clinical follow-up, involving routine care from a variety of clinical practices. The study includes an open-label, multicentric, non-randomized, single-arm, real-world evidence study design. The data were collected between the 20th of May 2021 and 31st of July 2021.

125 Real-world evidence studies are post-marketing studies bringing valuable information related 126 to the medical devices' safety and performance profiling and a broader understanding of the 127 practice pattern and the clinical outcomes. The rationale of the study was aimed at capturing safety data in a broader, more heterogenous population. Cerviron[®] vaginal ovules have been used 128 129 with success in the treatment of acute and chronic vulvovaginitis of mechanical etiology, and in 130 cervical lesions of mechanical origin, but with a limited number of study participants 131 (NCT04735705 and NCT04735718). Real-world evidence studies and clinical trials are 132 complementary. The present study is considered a real-world evidence study as it reflects actual 133 clinical aspects with data collected in the context of routine delivery of care, as opposed to data 134 collected within a clinical trial, where study design controls variability in ways that are not 135 representative of real-world care and outcomes.

The primary objective was to evaluate the tolerability of Cerviron[®] ovules in the treatment and management of cervical erosions of various etiologies. The secondary objective of this study was the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.

140 Study population. The target population included women aged 20 to 70 years with 141 symptomology associated with cervical ectropion of various etiology such as cervix trauma, 142 postpartum injuries, vaginal infections and cervicitis. A total of 345 women were evaluated. A number of patients were treated with Cerviron[®] ovules as monotherapy (n=210) and other 143 patients were prescribed Cerviron[®] ovules as an adjuvant in therapeutic schemas containing 144 145 antibiotics, antivirals and/or anti-inflammatory drugs (n=135). Subjects with a previous history 146 of any malignancy, including subjects with vulvar, vaginal, or cervical cancer or with 147 undiagnosed abnormal genital bleeding were excluded.

The study involved 30 Romanian specialist physicians as investigators from 16 institutions each treating between 6 and 22 patients. The participating clinical practices and their locations are listed as Table 1. Upon study entry and at 1, 2 and 3 months after the initial visit, participants

- 151 were interviewed and received visual cervical examinations by colposcopy. At each visit,
- 152 participants received a standardized pelvic exam with placement of a speculum and visualization
- 153 of the cervix.

Institution	City, Country (Romania)
Clinical Hospital 'Dr Ion Cantacuzino' Bucharest	Bucharest
Hospital MedLife Humanitas Cluj-Napoca	Cluj-Napoca
Medical office of Dr Saleh K. Majed	Craiova
Medical office of Dr Surpanelu Oana	Iasi
Natisan Medical Center	Pitesti
Gynecological office of Dr Rădulescu G. Mihaela Elena	Râmnicu Vâlcea
Medical office of Dr. Popescu	Sibiu
MediBlue Medical Clinic	Iasi
SC Pan Medical SRL	Sibiu
Medical clinic of Dr. Cioata Ionel Trifon	Timisoara
iMED Clinic	Sibiu
Tulcea County Emergency Hospital	Tulcea
Bradmed SRL	Targu Jiu
Gynecological office of Dr Ioana Trotea Targu Jiu	Targu Jiu
Medical office of Obstetrics and Gynecology of Dr Sirbu Daniela	Timisoara
SRL	
Dr Todorut Florina	Timisoara
Total sites, 16.	

155 Table 1. Clinical practices and their locations

Prospective data were collected from each patient, such as initial diagnosis, colposcopy examination results, re-epithelialization degree, vaginal pH value, vaginal symptoms, any worsening symptoms and adverse events.

Ethical and regulatory aspects of the study. Written consent for study participation was collected from all patients. General Data Protection Regulation (GDPR) consent forms were collected from all patients. Due to legal considerations (GDPR directive effective from 21 May 2018 in all European Union countries), patients or their legal representatives have an absolute right to request that their data be removed from the study database. A Notified Body (ENTE CERTIFICATIONE MACCHINE SRL) reviewed the post marketing clinical follow-up plan, including ethical considerations. As this is a post-marketing clinical follow-up study, an Ethics Committee approval was not required, as per the regulations described below.

167The study was conducted in accordance with the Guide to medical devices: 'Post-market168clinicalfollow-upstudies'169(https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-210325-

170 wng65.pdf) and the International Society for Pharmacoepidemiology (ISPE; 2015) Guidelines
171 for 'Good pharmacoepidemiology practices (GPP)'
172 (https://www.pharmacoepi.org/resources/policies/guidelines-08027/)

173 The collected data and study procedures were conducted in accordance with the ethical 174 principles that have their origin in the Declaration of Helsinki.

The study followed the definition of the non-interventional (observational) study provided by the Guide to Good Pharmacovigilance Practices (GVP; 2017): Module VIII - Post-authorization safety studies (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-goodpharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf).

The study followed the nature of the non-interventional (observational) studies mentioned in the
ICH Harmonized Tripartite Guide Pharmacovigilance Planning E2E (ICH, 2004;
https://database.ich.org/sites/default/files/E2E_Guideline.pdf).

Revision risk analysis was carried out in accordance with the medical device regulation, available from: https://www.anm.ro/en/dispozitive-medicale/regulamentele-europene-privinddispozitivele-medicale. Data were stored according to Annex E of ISO 14155:2020 (https://www.iso.org/standard/). The study and its details are registered in <u>www.clinicaltrials.gov</u> under ID NCT05668806.

Statistical consideration. All statistical analyses were performed using the Excel Analysis
ToolPak, version 16.69.1, from Microsoft. P<0.05 was considered to indicate a statistically
significant difference.

190 The quality and completeness of the collected data were preliminarily assessed in comparison 191 with data analysis. No study participant was involved in any violation of inclusion/exclusion 192 criteria. To examine the treatment significance over time, Fisher's exact test was performed for categorical variables, and Mann-Whitney U test was employed to perform comparative analysisfor variables non-normally distributed.

195 **Results**

196 Range of gynecological conditions and medical history of selected patients. The selected patients 197 presented with various gynecological conditions consistent with the instructions for the use of 198 the medical device. Some patients presented with other conditions with similar symptoms. As the 199 evaluation of the performance of the device was a secondary objective, other conditions that 190 would enable further investigations for expanding the use of the medical device were also 191 selected (Table 2).

Gynecological condition	Number of patients (n=345)
	Age, 20-70 years
Anexitis	4
Atypical squamous cells cannot exclude high grade squamous	5
intraepithelial lesion	
Atypical squamous cells of undetermined significance	39
Cervical dysplasia	7
Cervical ectropion	47
Cervicitis	59
Dyspareunia	6
Endocervicitis	8
Endocervicosis	11
Exocervicitis	61
Low-grade squamous intraepithelial lesions	6
Metroanexitis	2
Negative for intraepithelial lesion or malignancy	2
Ovarian cyst	2
Post Conization	10
Uterine fibroids	1
Uterus filaments	1
Vaginal atrophy	2
Vaginal polyps	1
Vaginal prolapse	1
Vulvovaginitis	70

202 203 Table 2. Medical history of selected patients

Subjects were followed undergoing treatment with Cerviron[®] vaginal ovules for ~3 months. 204 205 Each enrolled subject visited the clinic four times, at 30-day intervals each. The study visit scheme is listed in figure 1. In the monotherapy group, 11 patients (5.23%) were considered 206 207 dropouts due to the fact that they did not attend all the study visits and could not be evaluated. In the polytherapy group, 32 patients (23.7%) were considered dropouts (figure 1). 208



210 Figure 1. Schematic diagram for the present study.

Primary objectives. The study primary objective was to assess the tolerability of the medical device by the number of possible adverse reactions observed during the treatment. In one patient treated exclusively with Cerviron[®] ovules, during the routine gynecological examination one adverse reaction was noted, which was erythema. The erythema was followed by itching and abnormal vaginal discharge. The investigators determined that this was not related to treatment with the medical device. At the following visit, the reaction was absent.

Two other patients received combined treatment with antibiotics and Cerviron[®] ovules. After 30 days, both patients reported an adverse reaction of itching and erythema. Investigators determined that the symptoms were consistent with the initial diagnosis. After 60 days, these reactions were absent in both patients. All the aforementioned incidents were linked to preexisting conditions and the investigators decided that they must not be regarded as adverse reactions to the medical device Cerviron[®].

223 Secondary objectives

Clinical performance assessed by the investigator by colposcopy. A significant proportion of
69.14% patients were rated with the indicator 'normal aspect' during colposcopy, as shown in
figure 2.





228 Figure 2. Clinical performance assessed by the investigator by colposcopy

229 Re-epithelialization degree of the cervical mucosa by gynecological examination. For only 302 230 patients out of 345, medical records evaluating the degree of epithelialization of the cervical 231 mucosa were available. At the initial visit, 302 participants were assessed, of which 3.64% were 232 rated with 'complete epithelization', 40.40% were rated with degree of 'partial re-233 epithelialization' and 55,96% were rated with 'absent, ulcerations present'. At 30 days, 47.68% 234 of the 302 women assessed, had a favorable degree of re-epithelialization, with only 4.30% rated 235 as 'absent, ulcerations present'. After 3 months, 73.17% of the 287 patients were rated with 'complete epithelization', as shown in table 3. 236

Degree of re- epithelialization	Initial evaluation	At 30 days	At 90 days
Absent	169 (55.96%)	13 (4.30%)	6 (2.09%)
Partial	122 (40.40%)	145 (48.01%)	71 (24.74%)
Complete	11 (3.64%)	144 (47.68%)	210 (73.17%)
Total (N)	302	302	287

237

Table 3. Degree of re-epithelization at initial evaluation, 30 and 90 days.

239 *Vaginal pH level evaluation.* It was observed that following a 3-month treatment with 240 Cerviron[®], 87.86% of the patients presented with a normal pH, as revealed in figure 3.





Evaluation of the level of pain. Of the total number (n=302) of patients examined at visit 1, 46.67% reported mild pain levels and 28.00% had no pain at all. At the second visit, 68.49% of the population (207) rated pain severity as no pain or mild severity in 26.71%. A very high proportion (86.47%) was pain free at the last visit after 3 months of treatment with Cerviron[®] (as shown in figure 4). Figure 4 also provides the corresponding data related to pain level across the treatment period.



249

250 Figure 4. Evaluation of pain level between the study visits (90 days).

Evaluation of the level of vaginal bleeding. At the first visit, 302 women included in the study were evaluated, of whom 48.70% reported no bleeding observed after treatment with Cerviron® and 33.91% reported low amounts of vaginal bleeding. The efficacy of medical device was more

clearly observed at visit 2, where 77.68% of patients experienced no bleeding at all and 1.79%

255 experienced moderate or severe bleeding. After 3 months of treatment, this improvement was

noteworthy when 92.73% of patients reported no bleeding and only 7.27% of patients reported amild level of bleeding, as observed in figure 5.





259 Figure 5. Evaluation of the level of vaginal bleeding throughout the study (90 days).

260 *Degree of satisfaction after using Cerviron*[®] *ovules*. In terms of degree of satisfaction offered, 261 participants in the largest population (72.25%) were reported to be 'very satisfied' with the 262 medical device. The degree of satisfaction was measured by a 5-point Likert scale, as revealed in

263 figure 6. (30).



264

Figure 6. Likert Scale evaluation at the end of the study.

266 Discussion

267 A very important aspect that influences the management of cervical ectopy is age. Cervical 268 ectopy is predominant in young adolescents, with a prevalence of up to 80% in sexually active 269 adolescents. (31) However, factors associated with the evolution and devolution of cervical 270 ectopy are diverse and mechanisms have yet to be elucidated. Since ectopy is observed 271 frequently in adolescent girls and pregnant women, it may vary in response to hormonal 272 fluctuations observed in pregnancy and during contraception with combined oral contraceptives 273 (32). Screening for Chlamydia trachomatis and Neisseria gonorrhoeae can prevent a range of 274 gynecological conditions, such as urethritis, cervicitis, cervical erosions (33). Infection in the 275 lower genital tract can result in upper genital tract complications, such as pelvic inflammatory 276 diseases, ectopic pregnancy, chronic pelvic pain, and infertility in asymptomatic women, and 277 transmission of infection during pregnancy and labor (34).

278 Cryotherapy (cryosurgery) of the cervix is an effective treatment for symptomatic cervical 279 ectropion (35). Other surgical techniques have been applied for ablation of the squamocolumnar 280 junction. Cauterization has been applied for this purpose since 1920, but it involves additional 281 risks, such as burning lesions if the safeguard plate is not located correctly (36). Some 282 specialists even consider the cervical ectropion as a normal finding that does not require 283 treatment despite the red and inflamed appearance of the cervix. However, cervical ectropion is 284 considered as one of the most common types of chronic cervicitis worldwide (37). Topical 285 treatments for cervical ectropion, including cervical painting with gentian violet paint or 286 microwave tissue coagulation, are still widely used (4). Although the debate is still ongoing, a 287 harmonized treatment strategy would reduce complications of cervical ectropion, such as 288 developing abnormal metaplasia and/or vaginal infection. Applying an intervention to treat 289 cervical ectopy is recommended, especially when considering taking preventive action against 290 cervical cancer. Ectopic cells are modified over time by squamous metaplasia and 291 epithelialization, cervical infection with Neisseria gonorrhea or Chlamidia trachomatis, low pH values or trauma (38). Cerviron[®] appears to have a very potent action in rebalancing the vaginal 292 293 pH. In a previous clinical investigation, NCT04735705, vaginal pH values measured over 90 294 days showed that Cerviron[®] restores altered vaginal pH. The difference in vaginal pH values 295 between baseline versus 90 days, at a 5% significance level was statistically significant (P<0.05).

A literature review conducted by Machado *et al* indicated that treatment can be used to relieve occasional symptoms associated with ectopy, but does not support routine treatment for ectopy (12).

299 By contrast, a study conducted by Soares et al, showed a positive association between 300 cervical ectopy and human papillomavirus, HIV, bacterial vaginosis, cervical epithelial atypia, 301 postcoital bleeding, and desquamative inflammatory vaginitis (39). Recognition of cervical 302 ectopy should alert the clinician to the possibility of a genital chlamydia infection. Opportunistic 303 screening for chlamydia in young people should be offered to reduce the prevalence of infection 304 and its sequelae. Chlamydia trachomatis is the most common bacterial sexually transmitted 305 disease. In women, chlamydial infection usually presents as cervicitis, which can lead to up to 30 306 to 50% of pelvic inflammatory disease episodes. Pelvic inflammatory disease has significant 307 reproductive sequelae, such as tubal infertility and ectopic pregnancy (40).

308 The main mechanism of action of the medical device is the dispersion of the substances in 309 the vagina and the formation of a protective barrier that accelerates the natural healing process 310 of the damaged epithelium. The effect of the medical device is obtained due to the presence of 311 the Bismuth subgallate and vegetable collagen. Bismuth subgallate is an insoluble solution, with 312 a very low bio-availability which will create a physical barrier over the affected area of the 313 vaginal mucosa and therefore will not allow oxygen and pathogens to come in contact with it. In 314 this way, the substances create the premises that allow the damaged tissue to heal naturally. The 315 role of exogenous collagen is to be a " sacrificial substrate" in order to reduce excess 316 metalloproteins that delay wound healing and to regulate the healing of the damaged tissue (14, 317 40-43). As such, Cerviron[®] supportive therapy may be prescribed in sexually active patients for 318 at least 1-3 months, during 10-15 consecutive days, to prevent these infections.

The findings in the present study revealed that a 90-day treatment (3 treatment sessions of 30 days each) with Cerviron vaginal ovules was beneficial in providing a complete degree of cervical epithelialization and reduced the multitude of the vaginal symptoms, including bleeding, inflammation, malodor, dysuria, dyspareunia, pain and leukorrhea. This result is consistent with previous clinical studies that included the same medical device, NCT04735705 and NCT04735718 (46).

In conclusion, the findings of the present study revealed that administration of Cerviron[®] vaginal ovules provided a complete degree of epithelization in majority of patients attending a 327 90-days treatment. Moreover, subjects presenting a high grade of ulceration at the baseline visit, following treatment with Cerviron[®] presented a complete degree of epithelization. Cerviron[®] 328 329 ovules are an exceptional adjuvant for acceleration of healing of cervical erosions. They favor 330 the re-epithelialization of the damaged tissue and restoration of the initial colpo-ecosystem. Their 331 topical application was observed to be effective in reducing unpleasant symptoms such as 332 vaginal discharge, pelvic pain, and vaginal bleeding. In terms of adverse events, the medical device is considered safe. The only contraindication to Cerviron[®] ovules has been determined as 333 334 hypersensitivity to the active substance or to any of the excipients within the medical device.

335

336 Acknowledgements

We would like to thank Mrs Florentina Liliana Calancea (MDX Research, Timisoara, Romania)
for medical writing and Mr Alexandru Pinta (Labcorp Austria GmbH, Vienna Austria) for
support in data management and statistical analysis.

340 Funding

341 Perfect Care Distribution SRL (https://www.perfectcare.ro/), the study sponsor, offered the tested
342 medical devices and a partial grant support.

343 Availability of data and materials

344 The data that support the findings of this study are available from the corresponding author upon 345 reasonable request.

346 Authors' contributions

IP, RP and ADT were involved in the study design, methodology and original draft preparation.
IP and DTS performed the data collection and data analysis. RP, ADT and IP were involved in
analysis and interpretation of data. EP and FD-P were involved in manuscript review and editing.
IP, DTS and ADT participated in the interpretation of the study results. FD-P and EP confirm the
authenticity of all the raw data. All authors approved the final version of the manuscript to be
published.

353 Ethics approval and consent to participate

354 Only participants that voluntarily provided their written consent to the collection of their study 355 data were included. The collected data and study procedures were conducted in accordance with 356 the ethical principles that have their origin in the Declaration of Helsinki. Ethics committee/IRB

- 357 of Comisia Nationala de Bioetica a Medicamentului si a Dispozitivelor Medicale (CNBMDM)
- 358 waived the ethical approval for this work, according to the European Medical Device Regulation
- 359 MDR 2017/745, concerning data collected in the post-marketing clinical follow-up plan for
- 360 medical devices, Annex XIV, part B.

361 **Patient consent for publication**

362 Not applicable.

363 Competing interests

364 FD-P and EP are employed at Perfect Care Distribution SRL. RP and MDX Research, as CRO

365 provided services in another similar study. All other authors declare no conflicts. The funder

366 Perfect Care Distribution SRL had no role in the design of the study, or in the collection,

- 367 analyses, or interpretation of data, or in the writing of the manuscript, or in the decision to
- 368 publish the results.

369 **References**

- Wildenberg JC, Yam BL, Langer JE, Jones LP. US of the Nongravid Cervix with
 Multimodality Imaging Correlation: Normal Appearance, Pathologic Conditions, and
 Diagnostic Pitfalls. Radiographics. 2016 Apr;36(2):596–617.
- Ferenczy A. Benign Lesions of the Cervix. In: Blaustein A, editor. Pathology of the Female
 Genital Tract [Internet]. New York, NY: Springer; 1977 [cited 2022 Nov 22]. p. 124–42.
 Available from: https://doi.org/10.1007/978-1-4757-6143-6_6
- 376 3. Kuhn L, Denny L, Pollack AE, Wright TC. Prevalence of visible disruption of cervical
 approximate and cervical ectopy in African women using Depo-Provera. Contraception. 1999
 Jun;59(6):363–7.
- 4. Wright KO, Mohammed AS, Salisu-Olatunji O, Kuyinu YA. Cervical Ectropion and IntraUterine Contraceptive Device (IUCD): a five-year retrospective study of family planning
 clients of a tertiary health institution in Lagos Nigeria. BMC Res Notes. 2014 Dec 23;7:946.
- 382 5. Aggarwal P, Ben Amor A. Cervical Ectropion. In: StatPearls [Internet]. Treasure Island (FL):
 383 StatPearls Publishing; 2023 [cited 2023 Mar 22]. Available from:
 384 http://www.ncbi.nlm.nih.gov/books/NBK560709/
- 6. Mitchell L, King M, Brillhart H, Goldstein A. Cervical Ectropion May Be a Cause of
 Desquamative Inflammatory Vaginitis. Sex Med. 2017 Sep;5(3):e212–4.

- 7. Kleppa E, Holmen SD, Lillebø K, Kjetland EF, Gundersen SG, Taylor M, et al. Cervical
 ectopy: associations with sexually transmitted infections and HIV. A cross-sectional study of
 high school students in rural South Africa. Sex Transm Infect. 2015 Mar;91(2):124–9.
- 390 8. Goldacre MJ, Loudon N, Watt B, Grant G, Loudon JD, McPherson K, et al. Epidemiology
 391 and clinical significance of cervical erosion in women attending a family planning clinic. Br
 392 Med J. 1978 Mar 25;1(6115):748–50.
- 393 9. Dugas LR, Lie L, Plange-Rhule J, Bedu-Addo K, Bovet P, Lambert EV, et al. Gut microbiota,
 394 short chain fatty acids, and obesity across the epidemiologic transition: the METS395 Microbiome study protocol. BMC Public Health. 2018 Aug 6;18(1):978.
- Critchlow CW, Wölner-Hanssen P, Eschenbach DA, Kiviat NB, Koutsky LA, Stevens
 CE, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific
 cervical infection, smoking, and douching. Am J Obstet Gynecol. 1995 Aug;173(2):534–43.
- 399 11. Ortiz-de la Tabla V, Gutiérrez F. Cervicitis: Etiology, diagnosis and treatment. Enferm
 400 Infecc Microbiol Clin (Engl Ed). 2019 Dec;37(10):661–7.
- 401 12. Machado Junior LC, Dalmaso ASW, Carvalho HB de. Evidence for benefits from
 402 treating cervical ectopy: literature review. Sao Paulo Med J. 2008 Mar;126:132–9.
- 403 13. Straub RH. The Complex Role of Estrogens in Inflammation. Endocrine Reviews. 2007
 404 Aug 1;28(5):521–74.
- 405 14. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in
 406 cervical cancer cells | SpringerLink [Internet]. [cited 2023 Feb 14]. Available from:
 407 https://link.springer.com/article/10.1007/s11010-010-0606-3
- 408 15. Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, et al. Effects of estrogen on breast cancer
 409 development: role of estrogen receptor independent mechanisms. Int J Cancer. 2010 Oct
 410 15;127(8):1748–57.
- 411 16. Kassi E, Moutsatsou P. Estrogen Receptor Signaling and Its Relationship to Cytokines in
 412 Systemic Lupus Erythematosus. J Biomed Biotechnol. 2010;2010:317452.
- 413 17. Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang CY, McDonnell DP. Estrogen
 414 Receptor Signaling in the Immune System. Endocrine Reviews. 2023 Feb 1;44(1):117–41.
- 415 18. Rodriguez-Lara V, Peña-Mirabal E, Baez-Saldaña R, Esparza-Silva AL, García-Zepeda
- E, Cerbon Cervantes MA, et al. Estrogen receptor beta and CXCR4/CXCL12 expression:
- 417 differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. 2014
- 418 Feb;45(2):158–69.
- 419 19. De Luca Brunori I, Facchini V, Filippeschi M, Battini L, Giusti G, Romani L, et al. Cell420 mediated immunity in the course of cervical ectropion. Clin Exp Obstet Gynecol.
 421 1994;21(2):105–7.

- Wang LC, Yu Q, Edwards V, Lin B, Qiu J, Turner JR, et al. Neisseria gonorrhoeae
 infects the human endocervix by activating non-muscle myosin II-mediated epithelial
 exfoliation. PLoS Pathog. 2017 Apr 13;13(4):e1006269.
- 425 21. A S, A R, F C, S O. Cervical erosion as result of infectious vaginitis. European Journal of
 426 Experimental Biology. 2(5):0–0.
- 427 22. Çekmez Y, Şanlıkan F, Göçmen A, Vural A, Türkmen SB. Is Cryotherapy Friend or Foe
 428 for Symptomatic Cervical Ectopy? MPP. 2016;25(1):8–11.
- Yildiz S, Alay I, Eren E, Karaca I, Gultekin G, Kaya C, et al. The impact of cryotherapy
 for symptomatic cervical ectropion on female sexual function and quality of life. J Obstet
 Gynaecol. 2021 Jul;41(5):815–20.
- 432 24. Baram A, Paz GF, Peyser MR, Schachter A, Homonnai ZT. Treatment of cervical
 433 ectropion by cryosurgery: effect on cervical mucus characteristics. Fertil Steril. 1985
 434 Jan;43(1):86–9.
- Zhu T, Chen Z, Xia Q, Jiang S, Jin Q, Farahani MRD, et al. A suppository for treating
 cervical erosion and its preparation method. Clin Exp Obstet Gynecol. 2013;40(3):361–6.
- 437 26. Belfiore P, Costa E, De Cantis S, Vassallo R, Marino A. Effectiveness and persistence of
 438 a topical treatment for cervical ectropion with deoxyribonucleic acid. Minerva Ginecol. 2005
 439 Aug;57(4):461–6.
- 440 27. Bacalbasa N, Balescu IC. 2022-RA-462-ESGO The effects of Cerviron on vaginal
- 441 atrophy after surgically treated and adjuvant radiation therapy for cervical cancer.
- 442 International Journal of Gynecologic Cancer [Internet]. 2022 Oct 1 [cited 2023 Jan
- 443 25];32(Suppl 2). Available from: https://ijgc.bmj.com/content/32/Suppl_2/A391.1
- Bacalbasa N, Balescu I, Aloul A, Bohiltea R, Socea B, Ursut B, et al. The role of topic
 vaginal products in posthysterectomy vaginal atrophy. Romanian Medical Journal. 2021 Oct
 1;LXVIII:344–6.
- 447 29. 14:00-17:00. ISO 14971:2007 [Internet]. ISO. [cited 2022 Oct 14]. Available from:
 448 https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/03/81/38193.html
- 30. Robinson J. Likert Scale. In: Michalos AC, editor. Encyclopedia of Quality of Life and
 Well-Being Research [Internet]. Dordrecht: Springer Netherlands; 2014 [cited 2023 Mar 22].
 p. 3620–1. Available from: https://doi.org/10.1007/978-94-007-0753-5_1654
- 452 31. Bright PL, Turner AN, Morrison CS, Wong EL, Kwok C, Yacobson I, et al. Hormonal
 453 contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011
 454 Nov;84(5):512.
- 32. Bright PL, Turner AN, Morrison CS, Wong EL, Kwok C, Yacobson I, et al. Hormonal
 contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011
 Nov;84(5):512–9.

- 458 33. Pillay J, Wingert A, MacGregor T, Gates M, Vandermeer B, Hartling L. Screening for
 459 chlamydia and/or gonorrhea in primary health care: systematic reviews on effectiveness and
 460 patient preferences. Syst Rev. 2021 Apr 19;10:118.
- 461 34. Senn T. Sexually Transmitted Diseases (STDs). In: Gellman MD, Turner JR, editors.
 462 Encyclopedia of Behavioral Medicine [Internet]. New York, NY: Springer; 2013 [cited 2022
 463 Nov 22]. p. 1782–4. Available from: https://doi.org/10.1007/978-1-4419-1005-9_671
- 464 35. Agah J, Sharifzadeh M, Hosseinzadeh A. Cryotherapy as a Method for Relieving
 465 Symptoms of Cervical Ectopy: A Randomized Clinical Trial. Oman Med J. 2019
 466 Jul;34(4):322–6.
- 467 36. Chen J, Zhou D, Liu Y, Peng J, Li C, Chen W, et al. A comparison between ultrasound
 468 therapy and laser therapy for symptomatic cervical ectopy. Ultrasound Med Biol. 2008
 469 Nov;34(11):1770–4.
- 470 37. Liu Y, Yang K, Wu T, Roberts H, Li J, Tian J, et al. Microwave therapy for cervical
 471 ectropion. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD006227.
- 472 38. Machado Junior LC, Dalmaso ASW, Carvalho HB de. Evidence for benefits from
 473 treating cervical ectopy: literature review. Sao Paulo Med J. 2008 Mar 6;126(2):132–9.
- 474 39. Soares LC, Braz FLTA, Araújo AR, Oliveira MAP. Association of Sexually Transmitted
 475 Diseases With Cervical Ectopy: A Systematic Review. Sex Transm Dis. 2019 Jul;46(7):452–
 476 7.
- 40. Jacobson DL, Peralta L, Graham NMH, Zenilman J. Histologic Development of Cervical
 Ectopy: Relationship to Reproductive Hormones. Sexually Transmitted Diseases. 2000
 May;27(5):252.
- 480 41. Tramontina VA, Machado MAN, Nogueira Filho G da R, Kim SH, Vizzioli MR, Toledo
 481 S de. Effect of bismuth subgallate (local hemostatic agent) on wound healing in rats.
 482 Histological and histometric findings. Braz Dent J. 2002;13(1):11–6.
- 483
 42. Thorisdottir H, Ratnoff OD, Maniglia AJ. Activation of Hageman factor (factor XII) by
 484 bismuth subgallate, a hemostatic agent. J Lab Clin Med. 1988 Oct;112(4):481–6.
- 485
 43. Jafari B, Jafari-Sales A, Khaneshpour H, Fatemi S, Pashazadeh M, Al-Snafi AE, et al.
 486
 487 Antibacterial effects of Thymus vulgaris, Mentha pulegium, Crocus sativus and Salvia
 487 officinalis on pathogenic bacteria: A brief review study based on gram-positive and gram488 negative bacteria. Jorjani Biomedicine Journal. 2020 Oct 10;8(3):58–74.
- 489 44. Jafari B, Ahmadizadeh C. The In Vitro Study of Antimicrobial Effect of Marigold
 490 (Calendula officinalis) Extract on Infectious Microorganisms. Electronic Journal of Biology
 491 [Internet]. 2018 Jan 3 [cited 2023 Jan 23];13(4). Available from:
- 492 https://ejbio.imedpub.com/abstract/the-in-vitro-study-of-antimicrobial-effect-of-
- 493 marigoldrncalendula-officinalis-extract-on-infectious-microorganisms-21459.html

- 494 45. Dai C, Lin J, Li H, Shen Z, Wang Y, Velkov T, et al. The Natural Product Curcumin as
- 495 an Antibacterial Agent: Current Achievements and Problems. Antioxidants. 2022
 496 Mar;11(3):459.
- 497 46. Petrita R. Real-World Performance and Safety of Cerviron® Medical Device in the
 498 Treatment of Various Types of Vaginitis. BJSTR. 2022 Nov 22;47(2):38364–73.